Effects of BAY 41–2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus
- 1 April 2005
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 288 (4), L727-L733
- https://doi.org/10.1152/ajplung.00409.2004
Abstract
Nitric oxide (NO)-cGMP signaling plays a critical role during the transition of the pulmonary circulation at birth. BAY 41–2272 is a novel NO-independent direct stimulator of soluble guanylate cyclase that causes vasodilation in systemic and local circulations. However, the hemodynamic effects of BAY 41–2272 have not been studied in the perinatal pulmonary circulation. We hypothesized that BAY 41–2272 causes potent and sustained fetal pulmonary vasodilation. We performed surgery on 14 fetal lambs (125–130 days gestation; term = 147 days) and placed catheters in the main pulmonary artery, aorta, and left atrium to measure pressures. An ultrasonic flow transducer was placed on the left pulmonary artery (LPA) to measure blood flow, and a catheter was placed in the LPA for drug infusion. Pulmonary vascular resistance (PVR) was calculated as pulmonary artery pressure minus left atrial pressure divided by LPA blood flow. BAY 41–2272 caused dose-related increases in pulmonary blood flow up to threefold above baseline and reduced PVR by 75% ( P < 0.01). Prolonged infusion of BAY 41–2272 caused sustained pulmonary vasodilation throughout the 120-min infusion period. The pulmonary vasodilator effect of BAY 41–2272 was not attenuated by Nω-nitro-l-arginine, a NO synthase inhibitor. In addition, compared with sildenafil, a phosphodiesterase 5 inhibitor, the pulmonary vasodilator response to BAY 41–2272 was more prolonged. We conclude that BAY 41–2272 causes potent and sustained fetal pulmonary vasodilation independent of NO release. We speculate that BAY 41–2272 may have therapeutic potential for pulmonary hypertension associated with failure to circulatory adaptation at birth, especially in the setting of impaired NO production.Keywords
This publication has 41 references indexed in Scilit:
- Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart FailureCirculation, 2003
- Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 1998
- Role of ATP-sensitive potassium channels in ovine fetal pulmonary vascular toneAmerican Journal of Physiology-Heart and Circulatory Physiology, 1992
- Sustained fetal pulmonary vasodilation with prolonged atrial natriuretic factor and GMP infusionsAmerican Journal of Physiology-Heart and Circulatory Physiology, 1991
- Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birthAmerican Journal of Physiology-Heart and Circulatory Physiology, 1990
- Acute effects of partial compression of ductus arteriosus on fetal pulmonary circulationAmerican Journal of Physiology-Heart and Circulatory Physiology, 1989
- Adaptation of Fetal Pulmonary Blood Flow to Local Infusion of TolazolinePediatric Research, 1986
- Time-dependent response of fetal pulmonary blood flow to an increase in fetal oxygen tensionRespiration Physiology, 1986
- The vascular resistance of the foetal and newly ventilated lung of the lambThe Journal of Physiology, 1964
- Changes in the lungs of the new‐born lambThe Journal of Physiology, 1953